KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Other (2017 - 2025)

Amneal Pharmaceuticals has reported Receivables - Other over the past 9 years, most recently at $24.2 million for Q4 2025.

  • Quarterly results put Receivables - Other at $24.2 million for Q4 2025, up 441.87% from a year ago — trailing twelve months through Dec 2025 was $24.2 million (up 441.87% YoY), and the annual figure for FY2025 was $24.2 million, up 441.87%.
  • Receivables - Other for Q4 2025 was $24.2 million at Amneal Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Over the last five years, Receivables - Other for AMRX hit a ceiling of $100.0 million in Q2 2022 and a floor of $1.1 million in Q1 2021.
  • Median Receivables - Other over the past 5 years was $3.6 million (2024), compared with a mean of $11.8 million.
  • Biggest five-year swings in Receivables - Other: surged 7574.6% in 2022 and later plummeted 93.36% in 2023.
  • Amneal Pharmaceuticals' Receivables - Other stood at $1.2 million in 2021, then soared by 2710.26% to $33.1 million in 2022, then plummeted by 93.36% to $2.2 million in 2023, then skyrocketed by 103.0% to $4.5 million in 2024, then soared by 441.87% to $24.2 million in 2025.
  • The last three reported values for Receivables - Other were $24.2 million (Q4 2025), $2.2 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.